We are live on ! Find out more
EHI

Eagle Health Investments Portfolio holdings

AUM $603M
1-Year Est. Return 111.06%
This Fund
S&P 500
This Quarter Est. Return
+15.4%
1 Year Est. Return
+111.06%
3 Year Est. Return
+240.87%
5 Year Est. Return
+290.92%
10 Year Est. Return
–
AUM
$528M
AUM Growth
-$42.2M
Cap. Flow
-$91.6M
Cap. Flow %
-17.34%
Top 10 Hldgs %
71.71%
Holding
27
New
1
Increased
4
Reduced
8
Closed
2

Top Buys

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$17.6M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$15.7M
3
DXCM icon
DexCom
DXCM
+$14.4M
4
ILMN icon
Illumina
ILMN
+$8.46M
5
RARE icon
Ultragenyx Pharmaceutical
RARE
+$1.89M

Top Sells

Rank Stock Value
1
UTHR icon
United Therapeutics
UTHR
+$38.3M
2
IQV icon
IQVIA
IQV
+$25.8M
3
UNH icon
UnitedHealth
UNH
+$20.5M
4
GH icon
Guardant Health
GH
+$18.1M
5
TMDX icon
Transmedics
TMDX
+$17.7M

Sector Composition

Rank Sector Weight
1 Healthcare 98.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GH icon
26
Guardant Health
GH
$22.2B
– –
-626,909
Closed -$18.1M
IQV icon
27
IQVIA
IQV
$39.6B
– –
-121,895
Closed -$25.8M
1
2

Similar funds

IECM
Intrinsic Edge Capital Management Chicago, Illinois $603M AUM 66.97% 1-Year Est. Return
ERWM
Elk River Wealth Management Denver, Colorado $602M AUM 22.77% 1-Year Est. Return
CIG
Capricorn Investment Group Palo Alto, California $602M AUM 165.22% 1-Year Est. Return
JHCP
Jackson Hole Capital Partners Tulsa, Oklahoma $605M AUM 22.77% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
NPCM
North Peak Capital Management New York $601M AUM 0.2% 1-Year Est. Return
OCAM
Onex Canada Asset Management Toronto, Ontario, Canada $601M AUM 15.16% 1-Year Est. Return
GP
GSK plc London $599M AUM

Eagle Health Investments's Q3 2024 Portfolio in Review

As of Q3 2024, Eagle Health Investments held 27 positions worth $528M, down 7.4% from $570M the previous quarter. Its ten largest holdings account for 72% of the portfolio.

Eagle Health Investments withdrew a net $91.6M in Q3 2024, closing 2 positions and reducing 8 holdings. Its most notable exit was IQVIA, an estimated $25.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier.

Against the trend, Eagle Health Investments opened a new position in Neurocrine Biosciences worth $14.8M.

  • Eagle Health Investments's largest Q3 2024 buy was Neurocrine Biosciences: 128,600 shares worth $14.8M.
  • Eagle Health Investments added most to BioMarin Pharmaceuticals in Q3 2024, an estimated $15.7M increase.
  • Eagle Health Investments's biggest Q3 2024 reduction was United Therapeutics, cutting an estimated $38.3M.
  • Eagle Health Investments fully exited IQVIA in Q3 2024, selling an estimated $25.8M.
  • Eagle Health Investments's ten largest holdings make up 72% of its $528M portfolio in Q3 2024.
  • Eagle Health Investments opened 1 new position and closed 2 in Q3 2024.
  • Eagle Health Investments's portfolio value fell 7.4% quarter-over-quarter to $528M.

Based on Eagle Health Investments's 13F filing for Q3 2024, filed 12 Nov 2024.